



Published in final edited form as:

Eur Arch Psychiatry Clin Neurosci. 2019 February ; 269(1): 73–86. doi:10.1007/s00406-018-0976-1.

An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use

Alan J. Budney¹, Michael J. Sofis¹, and Jacob T. Borodovsky²

¹Center for Technology and Behavioral Health, Department of Psychiatry, Geisel School of Medicine at Dartmouth, 46 Centerra Parkway, Suite 315, Lebanon, NH, USA

²Department of Psychiatry, Washington University School of Medicine, St. Louis, USA

Abstract

Confusion and controversy related to the potential for cannabis use to cause harm, or alternatively to provide benefit, continues globally. This issue has grown in intensity and importance with the increased recognition of the public health implications related to the escalation of the legalization of cannabis and cannabinoid products. This selective overview and commentary attempt to succinctly convey what is known about one potential consequence of cannabis use, the development of cannabis use disorder (CUD). Such knowledge may help guide a reasonable and objective public health perspective on the potential impact of cannabis use and CUD. Current scientific data and clinical observation strongly support the contention that cannabis use, like the use of other substances such as alcohol, opioids, stimulants, and tobacco, can develop into a use disorder (addiction) with important clinical consequences. Epidemiological data indicate that the majority of those who use cannabis do not have problems related to their use, but a substantial subset (10–30%) do report experiencing symptoms and consequences consistent with a CUD. Treatment seeking for CUD comprises a substantial proportion of all substance use treatment admissions, yet treatment response rates show much room for improvement. Changing cannabis policies related to its therapeutic and recreational use are likely to impact the development of CUD and its course; however, definitive data on such effects are not yet available. Clearly, the development of more effective prevention and treatment strategies is needed for those vulnerable to developing a CUD and for those with a CUD.

Keywords

Cannabis; Cannabis use disorder; Marijuana; Policy; Prevalence; Treatment; Legalization

Introduction: does cannabis addiction exist and how do you define it?

Confusion, debate, and controversy related to the potential for cannabis use to cause harm, or alternatively to provide therapeutic benefit continues globally. Over the last decade, these

Compliance with ethical standards

Conflict of interest Neither author has any conflicts of interest other than research and training support from the NIH-NIDA.

issues have grown in intensity and importance with increased recognition of the substantial public health implications related to the escalation of (a) the decriminalization and legalization of cannabis and cannabinoid products, (b) the perception that cannabis has therapeutic potential for a numerous and diverse set of disorders, and (c) a burgeoning and lucrative cannabis industry. The seeming contradiction that a substance can cause harm and have therapeutic value is not unique to cannabis. Most substances (i.e., opioids, cocaine, stimulants, hallucinogens, tobacco, and even distilled alcohol) that have addictive potential, have also been deemed to have therapeutic potential and some have been used legitimately by medical providers. The current and pressing challenge with cannabis is to develop well-reasoned policies that consider factual information about risks and potential benefits of cannabis and cannabinoid compounds in service of mitigating potential harm and maximizing potential benefits.

This brief manuscript attempts to help address this challenge by conveying what is known about one potential harmful consequence of cannabis use, the development of cannabis use disorder (CUD), or what some refer to as cannabis addiction [1–3]. Although many people do not believe that cannabis has addictive potential, a large volume of scientific and clinical data demonstrate that a proportion of those who use cannabis do indeed develop an addiction that is much like that of other substance addictions [4]. Here, we provide a selective overview of the literature on CUD with associated commentary that highlights and discusses some key issues that contribute to misperceptions related to cannabis, and its potential consequences. To that end, we drew from (a) literature reviews and scientific articles on relevant topic areas identified in Pubmed using diverse search strategies, (b) articles cited in these reviews and articles, (c) the DSM-5 and its source materials, (d) databases and published reports from large epidemiological studies, and (e) select book chapters from recent texts on cannabis identified via google searches. Thus, this manuscript is not a systematic review of the scientific literature, rather, it is a selective overview and synthesis drawing from the large multidisciplinary literature relevant to the development and course of CUD. We end by providing some perspective on a pressing concern, that is, how might changes to the legal and regulatory status of cannabis impact the development of CUD and its consequences.

Because of the plethora of mixed messages about cannabis communicated to the public, policymakers, and health-care workers, we believe it is important to clearly define some key terms prior to discussing the CUD literature. First, when we use the word “cannabis”, we are referring to either the cannabis plant material or extracts from the cannabis plant that contain substantial amounts of tetrahydrocannabinol (THC). THC is the compound in the cannabis plant that produces the commonly desired euphoric-like effects (the “high”) [2, 5]. THC interacts with the CB1 receptor in the brain to stimulate the typical “high” sought by most cannabis users. This high produces the desire for repeated use, which for some cannabis users develops into a CUD [6 “Cannabis” in this article will not be referring to cannabidiol (CBD) products that contain no or very small amounts of THC. CBD is a compound in the cannabis plant that has recently generated a great deal of interest related to its potential therapeutic effects, and which does not produce euphoria when ingested [7]. Note that this working definition of “cannabis” as a substance that contains a substantive amount of THC is not the scientific definition of cannabis. It is used here because, when discussing the

addictive potential of cannabis, it is crucial to distinguish between cannabis products with THC versus those with primarily CBD.

Second, it is important to clarify what is meant by CUD. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [3] and the International Statistical Classification of Diseases and Related Health Problems (ICD-10 or 11) have clear operational definitions of a syndrome that can develop from excessive use of cannabis (and any other substance) [1]. The DSM-5 criteria for a diagnosis of CUD, which are generic for all substance use disorders, specify 11 signs and symptoms that relate to impaired control over one's consumption, social impairment, risky use, and physical dependence, i.e., tolerance or withdrawal. Severity of CUD can range from mild (meeting 2–3 criteria), to moderate (4–6 criteria), to severe (7 or more criteria). The ICD operationalizes CUD somewhat differently from the DSM-5. ICD-10 has two separate CUD disorders: harmful use and a dependence syndrome (i.e., similar to the abuse and dependence diagnoses of the previous version of the DSM). The diagnosis of harmful use is defined as a pattern of psychoactive substance use that is causing damage to health, which may be physical or mental. The dependence syndrome is defined as a cluster of physiological, behavioral, and cognitive phenomena in which the use of a substance takes on a much higher priority for a given individual than other behaviors that once had greater value. A dependence syndrome is diagnosed if a person meets three of six specified criteria.

The specification and inclusion of CUD in both DSM and ICD, which both use generic criteria across all addictive substance use disorders, communicate a few important realities about cannabis and its potential for “addiction”. First, health and medical experts and scientists consider CUD to be a valid and clinically important type of mental disorder that occurs in the general population, is not rare, and is experienced in much the same way as other SUDs [3, 8]. An overwhelming body of evidence for this assertion has accumulated and has been reviewed in detail elsewhere [9, 10]. The supporting data include research from nonhuman and human behavioral pharmacology, neuroscience and neuroimaging, genetics, clinical assessment and treatment, health service surveillance, and clinical epidemiology. Second, and particularly noteworthy, a valid cannabis withdrawal syndrome has been characterized such that a diagnosis of cannabis withdrawal disorder is included in the DSM-5 and experiencing withdrawal is one of the CUD diagnostic criteria.

In summary, CUD clearly develops and manifests in much the same way as other SUDs. The majority of those who have used cannabis do not develop a CUD, but among those that do, some develop a mild, some a moderate, and some a severe syndrome [11]. Below we review and discuss scientific information that we believe can assist readers to develop a reasonable public health perspective on CUD (see Table 1 for an overview of the primary issues probed in this review).

How prevalent is CUD and how severe are its associated consequences?

Cannabis is the most commonly used psychoactive and regulated drug in the world after alcohol and tobacco. In 2016, an estimated 192.2 million people had used cannabis within the past year for non-medical reasons [12]. Globally, from 1999 to 2015, cannabis use

prevalence remained fairly constant at approximately 4% [13]. In 2016, estimates of use in the U.S. among those 18 and older indicate that past-year and past-month cannabis use prevalence was 14.1% and 9.1%, respectively. This reflects an increase from that observed in 2002, when past-year and past-month prevalence was 10.4% and 6.0%, respectively [14]. For adolescents (ages 12–17), past-year and past-month cannabis use prevalence in 2016 was 12.0% and 6.5%, respectively, which reflects a decrease from 15.8 and 8.2%, respectively, in 2002.

When evaluating prevalence data, it is important to recognize that any one index of prevalence, e.g., past-month cannabis use, cannot adequately characterize the heterogeneity of clinically relevant use patterns. For example, of those who used cannabis in the past 30 days, 38% used it on only 1–5 days, whereas 50% used on 11 or more days, and 21% used every day. The distribution of days of use within the past month can also vary as a function of age and time. Consider that among past-month cannabis users who were 18 years and older, the prevalence of daily or near-daily cannabis use increased from 33.1% in 2002 to 43.0% in 2016, but declined from 29.8% in 2002 to 22.8% among adolescents. Given the heterogeneity of cannabis use patterns and the likely differential consequences associated with each, use of more fine-grained measures (e.g., # of days of use, times used per day, level of intoxication, method of administration) in epidemiological assessments of cannabis use is needed to better describe and differentiate risky patterns of cannabis use [15].

Efforts to determine the potential global harm resulting from cannabis use can in part be determined from estimates of global prevalence of CUD [16]. In 2010, an estimated 0.2% of the population or 13.1 million people met CUD [16]. In the U.S., two recent general population studies reported much higher, but discrepant past-year prevalence rates for CUD. The National Epidemiologic Survey of Alcohol and Related Conditions (NESARC) provided a past-year prevalence estimate of 3% (2013) in comparison with 1.5% estimate from the 2015 National Survey of Drug Use and Health (NSDUH) [11, 14]. Comparable estimates of CUD have been reported in other high-income nations such as Germany (0.5% in 2012 [17]) and Australia (1% in 2007 [18]). Interpretation of these global estimates of CUD should consider that most of the data comes from studies data that disproportionately sample higher-income nations, and often studies differ substantially on the proxy criteria items used to measure CUD [16].

Global estimates of CUD reflect a statistically nonsignificant increase in prevalence from 2002 to 2010 [16]. In the U.S., two estimates of trends in CUD over the past decade again diverged [11, 14, 19]. The NESARC study estimated an almost twofold increase in the prevalence of past-year CUD from 2002 to 2013 (1.5–2.9%) [20], while the NSDUH estimated a slight decrease from 2002 to 2013 (1.6–1.5%) [14]. Although it is difficult to synthesize these global and US estimates, a recent WHO report concluded that the prevalence of CUD is high enough to consider it a public health problem (at least in higher-income nations), and its prevalence appears to have increased since 2000 [12].

Conditional prevalence

Estimates of conditional prevalence of CUD provide one indication of the “addictive potential” of cannabis. Conditional prevalence is operationalized as the percentage of individuals with CUD among those who have ever used cannabis or among those who currently use cannabis. Data from the NESARC study indicate that nearly three out of ten (30%) past-year cannabis users met criteria for CUD in 2013 [20]. By contrast, in 2016, the NSDUH estimated past-year CUD in a much lower proportion of past-year cannabis users (11.6%) [21]. Although these point estimates differ substantially, both survey studies indicate that the prevalence of CUD among past-year users decline-potentially reflecting a greater prevalence of less severe cannabis use. Trends among adolescents, available only from the NSDUH, also indicate that the prevalence of CUD among those who had used cannabis during the past year decreased from 27.0% in 2002 to 20.4% in 2014.

Comparing conditional prevalence for CUD to that of other substances provides additional information with which to gauge the addictive potential of cannabis. The NESARC study estimated the prevalence of alcohol use disorder among past-year alcohol users to be 17.5% [22], which is somewhat lower than for CUD (30%). For tobacco use disorder, conditional prevalence of a use disorder among past-year tobacco users was much higher (80%) [23].

In summary, the epidemiological literature suggests that CUD is not rare, and that its addictive potential appears comparable to other substances that pose risk for development of a use disorder, higher than some, lower than others. Although tentative, evidence also points to increasing prevalence of CUD in the U.S. and other high-income nations. Given the changing legal landscape of cannabis in the US and other countries and its potential impact on cannabis product access and availability, systematic and repeated studies of the prevalence of CUD are needed to better inform public health laws and policy related to cannabis use.

Severity and Consequences of CUD

As mentioned above, the diagnostic criteria for CUD appear to perform similarly to other SUDs [4, 24]. The general SUD diagnostic criteria fit for CUD. The criteria are stable, reliable, fall into a unidimensional construct, and all of the 11 DSM criteria are reported by cannabis users [24, 25]. In 2013, the addition of cannabis withdrawal, both to the DSM-5 criteria list for CUD and as an independent withdrawal disorder, further supports the conclusion that CUD is highly similar to other SUDs. Cannabis withdrawal can contribute to sustaining use and increase the likelihood of relapse, although unlike some other substance withdrawal syndromes, it does not precipitate serious medical or psychiatric risk [26]. Consistent with this, CUD generally manifests as a somewhat milder use disorder than other SUDs (i.e., fewer diagnostic criteria are met per CUD diagnosis) [24, 25, 27].

The most recent NESARC study reported that the estimated distribution of lifetime severity levels of CUD in the U.S. were: mild (2.85%), moderate (1.42%), and severe (2.0%) [11]. Severity level was positively related to cannabis use frequency. Level of severity also showed a robust positive relationship with other mental health and substance use problems,

and a negative relationship to social, emotional, and cognitive functioning [11]. Hence, like other SUDs, the more severe the CUD diagnosis, the greater is the increase in the risk of physical and psychological symptoms that can negatively impact one's life.

CUD has also been associated with risk for other psychosocial problems. Those with CUD report greater disability [11, 28], report engaging in violent, suicidal and non-suicidal self-injurious behavior [29], and are more likely to report inpatient and emergency room visits than those without CUD [30]. Because those with CUD use cannabis more frequently than cannabis users without CUD [11], it warrants mention that increasing evidence has linked frequency of cannabis use, amount used, age of first use, and CUD severity with a wide array of cognitive impairments [31–34]. Further, some consequences that have been associated with CUD stem from the pharmacological effects of cannabis intoxication and chronic use (e.g., driving accidents, risky sexual behavior). Last, the degree to which cannabis use affects youth brain development and neurodevelopment processes is of increasing concern. Multiple basic and human laboratories have illustrated potential, harmful effects of cannabis use on neurodevelopment, and prospective studies are ongoing to try to determine the parameters of cannabis use (e.g., frequency per day/per month, age of initiation, THC concentration, quantity, etc.) that may independently or jointly underlie the development of CUD and related consequences [33, 35, 36].

Co-occurring disorders

Similar to other SUDs, those with CUD commonly have cooccurring psychiatric disorders and other types of SUDs [18, 37]. Data from the NESARC study indicate that compared to those without CUD, those with CUD during the past year are more likely to have additional SUDs (OR = 9.3) and psychiatric disorders such as anxiety disorders (OR = 2.8), personality disorders (OR = 4.8), mood disorders (OR = 3.8), and posttraumatic stress disorder (OR = 4.3) [11]. The most common SUDs that co-occur with CUD are alcohol (OR = 6.0) and nicotine (OR = 6.2). Co-use of tobacco among those with CUD has received increasing attention in the scientific literature, because it is associated with poorer clinical outcomes among those receiving treatment for CUD and because of the potential for additive health consequences from the inhalation of toxins from the smoke of combusted tobacco and cannabis products [38, 39].

Interestingly, among cannabis users, those with a psychiatric disorder are twice as likely to develop a CUD as those who do not have a disorder [40–43]. Moreover, the prevalence of psychiatric disorders among those who use cannabis appears to rise with increased frequency and severity of cannabis use suggesting that having a psychiatric disorder may increase the probability of transitioning from cannabis use to developing a CUD [44–47].

The high rates of co-occurrence of CUD and other psychiatric disorders raise multiple questions and concerns. Does this association reflect a tendency for those with other psychiatric disorders to use cannabis to alleviate symptoms associated with their other disorders, which eventually may develop into CUD? Are those who have psychiatric disorders particularly vulnerable to developing CUD once they initiate cannabis use? Or, does CUD, or the excessive cannabis use that drives it, make one vulnerable to the

development of other psychiatric disorders? How does CUD impact the course of existing psychiatric disorders? Is there a relationship between how much cannabis or specified compounds of cannabis are used and the direction of effects on psychiatric disorders? Here, we can only raise these issues and touch on what is known, however, a more comprehensive discussion of these concerns is available elsewhere [48, 49]. Notably, having a co-occurring CUD and psychiatric disorders, regardless of whether the CUD or the psychiatric disorder is experienced first, is strongly implicated in worse cannabis cessation outcomes and worse outcomes related to the psychiatric conditions (see [48] for a review). In contrast, there appears to be little data suggesting a positive relationship between cannabis use or CUD and the course of treatment outcome for persons with other psychiatric disorders.

Perhaps, the most clear implications from the research on CUD and co-occurring disorders are similar to that for other SUDs. First, providers need to be aware that many CUD patients will be experiencing other psychiatric symptoms or disorders, and optimal interventions may need to address these problems concurrently or sequentially. Second, those seeking treatment for many common psychiatric disorders should be screened for cannabis use and CUD, so that it can be evaluated, monitored, and strategically addressed in the context of treatment for those disorders. Last, the escalation of legal cannabis laws and implementation of the provisions of those laws, which increasingly include the “approval” of cannabis for therapeutic use for a number of psychiatric disorders, raises increasing concern about the impact of cannabis use and CUD on the course and treatment of psychiatric disorders and the converse. We discuss this concern in more detail below.

Do people seek treatment for CUD?

Emerging data from 22 European nations suggest first-time treatment admissions for cannabis as the primary substance of concern are highly prevalent and increased from 2003 to 2014 [50]. The United Nations Office on Drugs and Crime estimated that from 2003 to 2016 the proportion of all SUD treatment admissions that were for cannabis increased from roughly 8–15% in eastern and southeastern Europe, 19–30% in western and central Europe, 29–48% in Oceania, 9–16% in Asia, 28–33% in North America, and decreased from roughly 64–51% in Africa [13].

Total SUD treatment admissions in the U.S. from 2002 to 2015 declined to 18.6% (see the Treatment Episode Data Set (TEDS) [51]). Primary cannabis treatment admissions decreased at a noticeably greater rate from 2002 to 2015 (26%) [51]. As a proportion of all SUD treatment admissions, primary cannabis treatment admissions demonstrated a modest decrease from 15.3% (288,418) of total admissions in 2002 to 13.9% (213,001) in 2015. The observation that there was a greater reduction in cannabis admissions than that of total SUD admissions may be linked to how CUD patients are referred to treatment. The TEDS survey indicated that 50.7% of admissions in 2015 were mandated by a court or juvenile justice referral, which is about 20% greater than that for admissions for alcohol (33.2%) and cocaine (28.3%). Whether or not the changing legal status of cannabis across the U.S. has impacted rates of treatment seeking is difficult to determine, but these data suggest a potential contribution. Of note, the proportions of referrals from other sources for cannabis admissions were: self or family (18.7%), alternative community referral (16.5%), substance

abuse care provider (4.7%), alternative health care provider (4.7%), school (3.4%), or employer (0.6%).

The number of adolescent (i.e., ages 12–17) treatment admissions for all SUDs decreased by 58.1% from 2002 to 2015, and the number of primary cannabis-related admissions decreased by 50.1% [52, 53]. However, unlike the admission data for all age groups, the proportion of adolescent SUD treatment admissions that were for CUD rose from 63% in 2002 to 76% in 2015. Interestingly, data from the 2017 Monitoring the Future annual U.S. survey showed that the risk perception of harm from regular cannabis use among 8th, 10th, and 12th grade students in 2017 was the lowest since 1990 [54].

Although these data indicate substantial treatment seeking for CUD, it is estimated that in the U.S., only 7–8% of individuals with CUD have utilized treatment that is specific to cannabis in the past year [11, 55]. Although this may seem surprisingly low, only 13.5% of individuals with any past-year SUD received treatment in the U.S [56, 57]. This U.S. percentage of treatment engagement is considerably lower than other high-income nations. For example, in Australia, 36% of those with CUD seek treatment [18]. Potential factors that may contribute to the lack of treatment utilization include desire for self-reliance, perceptions that treatment is not necessary, a lack of awareness of the problem, and stigma [58, 59]. Adults seeking treatment for CUD attribute multiple problems to their cannabis use (e.g., procrastination/low productivity, memory issues, low energy, financial or employment difficulties, guilt about use, cannabis withdrawal, low self-confidence/self-esteem, insomnia, and distressed personal relationships) [60, 61], as do adolescents (e.g., neglected responsibilities, not able to do homework or study, missed school or work, went to school high, missed out on things because they spent too much money on cannabis, had arguments with family, and continued using despite promising oneself not to, and noticed unpleasant changes in personality) [62]. Interestingly, despite attributing such problems to cannabis, only 34% of these youth deemed their cannabis use a problem [62].

To better identify who may be in need of and benefit from treatment, a number of validated brief screening instruments have been developed to identify persons at risk for cannabis-related problems, e.g., Cannabis Use Identification Test (CUDIT-R), the Cannabis Abuse Screening Test (CAST), Cannabis Use Problems Identification Test (CUPIT), Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), the Marijuana Problem Index (MPI), and the Cannabis Problems Questionnaire for Adolescents (CPQ-A) [63–69]. These instruments can be self-administered, and thus easily incorporated in most healthcare settings or used for self-evaluation. A growing literature has demonstrated that pairing such assessments with brief motivational interventions can be effective for reaching those with CUD outside of specialty SUD clinics [70], as we discuss in the following section.

How difficult is it to quit or reduce cannabis use?

As documented above, similar to those who use other substances, a proportion of those who use cannabis who are experiencing problems related to their use enter treatment indicating a desire or need to stop or reduce their use, while others try to quit without professional

assistance. This raises an important question relevant to understanding the implications of developing a CUD: how difficult is it to quit or substantially reduce cannabis use?

Multiple sources of data provide some insight on this change process and subsequent outcomes. First, a few prospective, non-treatment studies that followed individuals who were contemplating reducing or quitting their cannabis use suggest that change is not easy. The most intensive, but short-term study was conducted in the U.S. and obtained daily data from primarily adults who used cannabis daily (most also met criteria for a CUD), who intended to stop or reduce use in the next 3 months [71]. Findings replicated a smaller previous study [72] illustrating that participants tended to make multiple brief quit or reduction attempts, many transitioned between periods of reduced use, abstinence, and usual use patterns, and very few achieved sustained abstinence or sought treatment [71, 73].

General population studies from three different countries have assessed remission rates over time for those with CUD and other SUDs [74]. Annual remission rates for CUD, defined as no longer meeting criteria for active CUD, were estimated at 17%. This rate was marginally higher than opioid use disorder (10–20%) and cocaine use disorder (5–13%), and about the same as stimulant use disorder (16%). Another study conducted in Germany focused solely on cannabis use among young adults and reported similar results [75]. Approximately, 15% of those with CUD and 25–39% of regular heavy users who did not meet CUD criteria were no longer using cannabis 3–4 years later. Although these conclusions must be considered tentative given the limitations of the individual studies, they are consistent with other natural history study observations that illustrate both the recalcitrant nature of cannabis use among those with CUD or who use daily, and the natural progression towards reduced use or cessation during the lifespan.

The clinical trials' research on CUD provides a similar perspective on how difficult it is to stop or substantially reduce cannabis use. In the past 8 years, numerous reviews of this literature have provided similar synopses and converge on similar conclusions [4, 12, 48, 76–83]. More than 30 published controlled trials have most commonly evaluated three psychosocial treatment approaches: motivational enhancement (MET), cognitive-behavioral (CBT) and contingency management (CM) interventions. As with treatment research on other SUDs, methodological variability across studies, such as the lack of uniform outcome measures, few comparisons to non-treatment controls, heterogeneous samples, and variable lengths of treatment and post-treatment follow-up, make it difficult to systematically combine findings across studies and evaluate the relative efficacy of treatment approaches. That said, "positive" outcomes at the individual level (i.e., abstinence or substantial reduction in use) with these interventions have ranged from approximately 20–53% when assessed at the end of treatment to 15–45% at 6- or 12-month follow-ups, with results from most studies being at the lower half of these success ranges [4, 12, 48, 76–83]. The majority of the reviews suggest that adding CM, i.e., monetary incentives provided contingent on documented abstinence, to MET, CBT or their combination, has demonstrated the most robust treatment effects across clinical trials. This literature also suggests that more intense psychosocial treatments over longer intervals (i.e., four or more sessions) appear more robust than the briefer motivational approaches.

Brief interventions for CUD (i.e., typically 1–2 sessions), which primarily utilize interviewing strategies drawn from the motivational interviewing literature, have demonstrated small to moderate effects, and have been investigated in specialty and non-specialty treatment settings (see reviews: [83, 84]). The availability of these more accessible and less burdensome approaches is particularly important for reaching a larger proportion of those with CUD who might benefit from treatment.

Similarly, the recent exploration of technology-delivered (“digital”) health interventions (DHIs) to prevent escalation of cannabis use and to treat CUD offers great potential for extending the reach and enhancing outcomes of evidence-based treatments (see reviews: [83, 85, 86]). Such DHIs have been tested as in-clinic and remote alternatives to therapist-delivered behavioral counseling. Some have been designed to use as an adjunct to in-person counseling or pharmacotherapy, and others as web-accessed, stand-alone interventions for the general public. And, others have been used as alternatives to in-person brief interventions in university health centers and pediatric and primary care health settings [83, 85]. To date, more robust outcomes with DHIs have been reported when patients receive at least minimal contact with a therapist. Nonetheless, the small effects observed with brief DHIs in medical settings and stand-alone internet accessed TDIs [87] have substantial public health implications because of their potential to reach those who would not otherwise access treatment.

The scientific literature on treatment approaches for youth with CUD has produced findings similar to that with adults. Multiple reviews published in the last decade indicate that a number of well-specified individual, group, and family-based interventions are efficacious, and benefit a significant proportion of youth [88–95]. However, like with adults, the majority of youth who enter these treatment studies typically do not show evidence of a clinically meaningful response, and relapse rates are substantial. A few individual trials report on interventions with greater response rates (e.g., MDFT: [96]), but as with the adult literature, the substantial variability in study sample characteristics and outcome measures, make it difficult to compare results across trials. A recent review suggests that combining/integrating evidence-based approaches to broaden the scope of the intervention appears to enhance outcomes for youth who enroll in treatment for SUD [88, 95]. As in the adult literature, brief interventions and innovative DHIs are being developed and tested in attempts to extend the reach and enhance the efficacy of interventions for youth with SUDs including CUD [97].

Last, a growing literature that includes human laboratory studies and clinical trials has evaluated the potential of various medications as stand-alone or adjunct treatments for those with CUD. Targets of these medications include (a) reduction in withdrawal or cessation of use with agonist-like medication that target the CB1 receptor (substitution therapies), (b) specific withdrawal symptoms or relapse triggers such as mood, sleep, or craving, (c) reduction in the reinforcing effects of cannabis with antagonist or inverse agonist medications that “block” the CB1 receptor or opioid receptors that interact with the cannabinoid system, and (f) comorbid psychiatric conditions that may partially contribute to ongoing use of cannabis to relieve psychiatric symptoms. Multiple reviews of this pharmacotherapy literature illustrate that we have yet to identify medications that are effective for engendering cannabis abstinence or significant reductions in use [6, 82, 98–

101]. Some positive signals of potential efficacy have been observed for a few medications, but replication studies have either failed to confirm the results or have not been reported.

Overall, the findings from CUD intervention studies with adults and youth clearly indicate that successful outcomes are not easily achieved. Rates of response appear comparable to outcomes achieved with other SUDs, although drawing firm conclusions about their relative efficacy is tenuous because of the lack of rigorous comparative studies [4, 79, 82, 102]. The observations from natural history and controlled treatment studies, by and large, strongly suggest the need for continued exploration and development of intervention approaches that can positively impact a greater number of those who develop CUD.

How will the changing cannabis legal and regulatory environment impact the development of CUD?

Concerns about potential adverse consequences of relaxing legal and regulatory restrictions on the sale and use of cannabis products, particularly on youth, have been raised and debated in governmental bodies, the scientific literature, and the press. Of most relevance to the present discussion is the impact of this changing legal landscape on CUD development and its course. Some assert and we agree that empirical data on this issue that come primarily from the U.S. are equivocal and premature [103]. However, a careful reading of literature combined with knowledge of well-established risk factors for the development of SUDs, including CUD, strongly suggest that without thoughtful regulatory and preventative actions to counter the potential negative impact of lax cannabis policies and regulations, one can expect increases in cannabis use and CUD over time, particularly among those most vulnerable [9, 48, 103–105].

We have previously discussed three “risk factors” for the development of CUD that can be moderated by regulatory policy and provisions: pharmacology of drug effects, access/availability of substances, and environmental influences [9]. Related to pharmacological effects, changes in cannabis laws have been accompanied by changes in the availability of much more potent (high %THC) products and alternative drug delivery methods (vaporizers, dab rigs, edibles). The products now available on the street and in cannabis dispensaries include cannabis plant material products that contain up to 25–35% THC, and cannabis “concentrate” products that contain up to 85% THC. Such products and delivery methods may (a) provide more efficient delivery of the psychoactive effects, (b) produce more reinforcing effects and (c) perhaps expedite the development of tolerance and withdrawal [106–109]. These potential effects can contribute to the development of CUD or any SUD by increasing the likelihood of repeated use and the desire to use a greater amount of the active compound, which for cannabis is THC [110].

Specific provisions and regulatory frameworks within legal cannabis laws can impact the degree of access to cannabis products or devices. Such access effects are often underestimated but they should not be given what has been observed in the alcohol and tobacco fields [111, 112]. Access is determined by multiple factors including cost and proximity which determine how much effort is required to obtain a substance, in addition to the simple availability of the products for purchase [113]. These facets of availability

interact with the pharmacological effects of the substance to influence use initiation, and amount, frequency, and continuation of use.

A few examples unique to the current cannabis landscape warrant mention. First, the increased availability of vaping devices and edible cannabis products have provided ways for individuals to use cannabis that are perceived as “safer” [114, 115]. These methods allow cannabis to be administered without inhaling toxic smoke that contains carcinogenic material. Of concern, however, is that vaping and edible use may entice a subset of youth or adults to initiate or reinstate cannabis use, who otherwise may have avoided use because of concerns related to smoking [107]. Moreover, not having to ingest smoke may also increase use among those who had previously used or currently use cannabis. Other access-related regulatory provisions such as those allowing home cultivation of cannabis can also make cannabis more readily available and reduce cost of various cannabis products including those with high potency [116].

Most experts predicted that cannabis legalization and commercialization would result in a substantial decrease in cost compared to pre-legalization costs [103, 117], and indeed, emerging evidence of changing cannabis prices corroborates those predictions. These data are concerning because of fundamental economic principle: lower cost results in increased purchases. This relationship has been clearly demonstrated in the alcohol and tobacco fields, and will assuredly apply to cannabis products [118–121]. Manipulating the cost of products primarily through taxation has been a successful public health strategy for alcohol and tobacco, and many States in the U.S. are now experimenting with how best to tax cannabis manufacturing and sales.

Two “environmental” factors, marketing and social norms, related to the changes in cannabis policies are particularly important to address in relation to how they may influence the development of CUD. First, as with cost effects, the impact of advertising and marketing on the tobacco and alcohol industries has been well-researched. A primary marketing strategy used in those industries is to normalize use by shaping beliefs and expectations with the goal of prompting initiation and sustaining regular and heavy use, because most sales and profits come from heavier users and those with use disorders [122–124]. Youth are appealing targets for this strategy, because earlier age of onset of substance use robustly predicts risk for the development of later tobacco, alcohol and cannabis use disorders [125–131]. As would be predicted given the emergence of a multi-billion dollar cannabis industry, data connecting cannabis marketing and age of initiation are beginning to emerge [132–135]. Marketing and advertising are rampant in many states, as the cannabis industry already has a strong presence on the internet. As such, one can expect the burgeoning cannabis industry will capitalize on lax restrictions and effectively engage in practices designed to prompt use, particularly among those vulnerable for developing CUDs [118, 135–138].

The escalation of the sanctioning of cannabis use for therapeutics and recreation combined with the marketing and advertising of the cannabis industry most likely impacts beliefs about the effects of cannabis, social norms, and perceptions of risk related to cannabis use. This raises multiple concerns for persons with or at risk for developing psychiatric conditions, because they are also at greater risk for developing a co-occurring CUD. We

have reviewed such concerns extensively elsewhere [48], hence here we briefly broach two issues. First, and perhaps most troubling is the government approval of cannabis for psychiatric and other medical conditions combined with the cannabis industry's marketing of cannabis products for such conditions. Such marketing is occurring without clinical evidence of therapeutic efficacy and with extant data showing potential adverse effects on most psychiatric conditions. Encouraging cannabis use in these vulnerable populations, particularly given the availability of alternative effective therapies, can undermine recovery or management of their psychiatric conditions, and perhaps increase the probability of developing a psychiatric disorder [48].

Second, a reduction in perceived risk of cannabis combined with the increased belief that cannabis can be a therapeutic agent for multiple medical conditions may have significant influence on treatment seeking among those with CUD. The number of states with legal cannabis laws has increased nearly threefold from 2009 to 2015, while the percentage of cannabis-related adult treatment admissions relative to other SUD admissions has decreased by approximately 30–40%. As per above, approximately half of referrals to treatment for cannabis problems in the U.S. have come from legal or judicial sources. With legal consequences likely to decrease in the current cannabis regulatory environment, self-recognition or family/friend recognition of a cannabis problem will become more necessary to prompt persons with CUD to get help. If perceptions of cannabis-related harm continue to decrease, the probability of recognizing and attributing problems to cannabis use will also be reduced. Such an effect would be particularly undesirable, because self or family/friend referrals for cannabis-related treatment admissions are already low compared to those for other SUDs [53].

In summary, legalization of cannabis for therapeutic or recreational use has the potential to substantially impact cannabis use initiation, use patterns, and the development and course of CUD. Such effects can manifest via multiple mechanisms, many of which are well-known risk factors for substance use and addiction in general. Studies of the effects of cannabis legalization are ongoing. However, at present, definitive data concerning the impact of cannabis legalization are not yet available in large part, because such legislative changes are both nascent and diverse. Nonetheless, existing clinical and social science on the nature of addiction, together with knowledge about cannabis use and CUD, can be used to effectively inform regulatory provisions and preventative measures that can help mitigate potential harms that may accompany legalization.

Conclusions

Current scientific knowledge and clinical observation strongly support the contention that cannabis use—like the use of other substances such as alcohol, opioids, stimulants, and tobacco—can develop into a use disorder, a.k.a., an addiction, that has substantial clinical consequences. The clinical epidemiology studies reviewed here indicate that at least one in ten of those who currently use cannabis self-report having problems that meet the criteria for a use disorder as indicated in the DSM and ICD. These data also indicate that the majority of those who use cannabis do not have problems related to their use, but an important subset may develop a CUD. Among those that develop a CUD, the severity of the disorder ranges

from mild to severe, and the severity level appears to be positively related to deficits in cognitive and psychological functioning. A small but substantial proportion of those with CUD seek treatment, and these patients make up a substantial proportion of all admissions for SUDs; indeed for youth, they make up the great majority of all admissions. Additional research is needed, however, to better estimate the prevalence of CUD and how it relates to rates of treatment seeking. The clinical trials research on CUD with both adults and adolescents clearly demonstrates that a number of behavioral treatments are efficacious. Unfortunately, these studies also show that the majority of patients who receive these interventions do not show evidence of clinically meaningful positive change in their cannabis use, illustrating that quitting cannabis for those with CUD is difficult. Most noteworthy is that each of the statements above can be applied to all other licit and illicit substances that humans use recreationally and that are known to have addictive potential.

It is of clear public health importance that we: (a) continue to educate the public, our policymakers, and our healthcare providers on the potential harms which can occur from the use of cannabis products that contain significant amounts of THC; (b) develop and implement cannabis regulatory policies that seek to mitigate the potential for known negative consequences of cannabis use, particularly in populations that are vulnerable to the development of CUD; and (c) foster clinical research on prevention and treatment that can more effectively assist those at risk for and those who are currently experiencing the consequences of CUD.

References

1. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. World Health Organization, Geneva
2. Zehra A, Burns J, Kure Liu C, Manza P, Wiers C, Volkow N, Wang G (2018) Cannabis addiction and the brain: a review. *J Neuroimmune Pharmacol* 1–15. 10.1007/s11481-018-9782-9
3. APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn American Psychiatric Publishing, Arlington
4. Budney AJ, Roffman R, Stephens RS, Walker D (2007) Marijuana dependence and its treatment. *Addict Sci Clin Pract* 4(1):4–16 [PubMed: 18292704]
5. Bloomfield MAP, Ashok AH, Volkow ND, Howes OD (2016) The effects of Δ^9 -tetrahydrocannabinol on the dopamine system. *Nature* 539:369 10.1038/nature20153 [PubMed: 27853201]
6. Vandrey R, Haney M (2009) Pharmacotherapy for cannabis dependence: how close are we? *CNS Drugs* 23(7):543–553 [PubMed: 19552483]
7. Sohly EI (2005) Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sci* 78:539–548 [PubMed: 16199061]
8. Budney AJ, Lile JA (2009) Moving beyond the cannabis controversy into the world of the cannabinoids. *Int Rev Psychiatry* 21(2):91–95. 10.1080/09540260902782729 [PubMed: 19367502]
9. Budney AJ, Borodovsky JT (2017) The potential impact of cannabis legalization on the development of cannabis use disorders. *Prev Med*. 10.1016/j.ypmed.2017.06.034
10. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008) Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. *J Subst Abuse Treat* 35(4):362–368. 10.1016/j.jsat.2008.01.002 pii] [PubMed: 18342479]
11. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF (2016) Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions–III. *Am J Psychiatry* 173(6):588–599. 10.1176/appi.ajp.2015.15070907 [PubMed: 26940807]

12. WHO (2016) The Health and social effects of nonmedical cannabis use. Geneva, Switzerland
13. UNODC (2018) World drug report: pre-briefing to the member states United Nations Office on Drugs and Crime, Vienna
14. SAMHSA (2017) Results from the 2016 national survey on drug use and health: detailed tables Prevalence estimates, standard Errors, P Values, and sample sizes. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, Rockville
15. Mauro PM, Carliner H, Brown QL, Hasin DS, Shmulewitz D, Rahim-Juwel R, Sarvet AL, Wall MM, Martins SS (2018) Age differences in daily and nondaily cannabis use in the United States, 2002–2014. *J Stud Alcohol Drugs* 79(3):423–431. 10.15288/jsad.2018.79.423 [PubMed: 29885150]
16. Degenhardt L, Ferrari AJ, Calabria B, Hall W, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T (2013) The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study. *Plos ONE* 8(10):e76635 10.1371/journal.pone.0076635 [PubMed: 24204649]
17. Pabst A, Kraus L, Gomes de Matos E, Piontek D (2013) Substance use and substance use disorders in Germany in 2012. *SUCHT* 59:321–331
18. Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, Grove R, Newton N, Hall W (2012) Prevalence, correlates and comorbidity of DSM-IV cannabis use and cannabis use disorders in Australia. *Aust N Z J Psychiatry* 46(12):1182–1192 [PubMed: 22984111]
19. Gruzca RA, Agrawal A, Bierut LJ (2016) NESARC Findings on increased prevalence of marijuana use disorders—reply consistent with other sources of information. *JAMA Psychiatry* 73(5):532–533. 10.1001/jamapsychiatry.2016.0244
20. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF (2015) Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. *JAMA Psychiatry* 72(12):1235–1242. 10.1001/jamapsychiatry.2015.1858 [PubMed: 26502112]
21. Gruzca RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ (2016) Recent trends in the prevalence of marijuana use and associated disorders in the United States. *JAMA Psychiatry* 73(3):300–301. 10.1001/jamapsychiatry.2015.3111 [PubMed: 26864618]
22. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, Hasin DS (2017) Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the national epidemiologic survey on alcohol and related conditions. *JAMA Psychiatry* 74(9):911–923. 10.1001/jamapsychiatry.2017.2161 [PubMed: 28793133]
23. Chou SP, Goldstein RB, Smith SM, Huang B, Ruan WJ, Zhang H, Jung J, Saha TD, Pickering RP, Grant BF (2016) The epidemiology of DSM-5 nicotine use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. *J Clin Psychiatry* 77(10):1404–1412. 10.4088/JCP.15m10114 [PubMed: 27135834]
24. Budney AJ (2006) Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue? *Addiction* 101:125–133 [PubMed: 16930169]
25. Shmulewitz D, Greene ER, Hasin D (2015) Commonalities and differences across substance use disorders: phenomenological and epidemiological aspects. *Alcohol Clin Exp Res* 39(10):1878–1900. 10.1111/acer.12838 [PubMed: 26332166]
26. Budney AJ, Hughes JR (2006) The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 19(3):233–238 [PubMed: 16612207]
27. Peer K, Rennert L, Lynch KG, Farrer L, Gelernter J, Kranzler HR (2013) Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. *Drug Alcohol Depend* 127(0):215–219 [PubMed: 22884164]
28. Kerridge BT, Pickering R, Chou P, Saha TD, Hasin DS (2018) DSM-5 cannabis use disorder in the national epidemiologic survey on alcohol and related conditions-III: gender-specific profiles. *Addict Behav* 76:52–60 [PubMed: 28755613]
29. Kimbrel N, Meyer E, DeBeer B, Gulliver S, Morissette S (2018) The impact of cannabis use disorder on suicidal and nonsuicidal self-injury in Iraq/Afghanistan-era veterans with and without mental health disorders. *Suicide Life Threat Behav* 48(2):140–148 [PubMed: 28295524]

30. Campbell CI, Bahorik AL, Kline-Simon AH, Satre DD (2017) The role of marijuana use disorder in predicting emergency department and inpatient encounters: a retrospective cohort study. *Drug Alcohol Depend* 178:170–175 [PubMed: 28651153]
31. Crean RD, Crane NA, Mason BJ (2011) An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. *J Addict Med* 5(1):1–8. 10.1097/ADM.0b013e31820c23fa [PubMed: 21321675]
32. Kowal MA, van Steenbergen H, Colzato LS, Hazekamp A, van der Wee NJA, Manai M, Durieux J, Hommel B (2015) Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users. *Eur Neuropsychopharmacol* 25(11):1943–1953 [PubMed: 26298832]
33. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. *JAMA Psychiatry* 73(3):292–297. 10.1001/jamapsychiatry.2015.3278 [PubMed: 26842658]
34. Solowij N, Battisti R (2008) The chronic effects of cannabis on memory in humans: a review. *Curr Drug Abuse Rev* 1(1):81–98 [PubMed: 19630708]
35. Lorenzetti V, Alonso-Lana S, Youssef GJ, Verdejo-Garcia A, Suo C, Cousijn J, Takagi M, Yücel M, Solowij N (2016) Adolescent cannabis use: what is the evidence for functional brain alteration? *Curr Pharm Des* 22(42):6353–6365. 10.2174/1381612822666160805155922 [PubMed: 27514709]
36. Jernigan TL, Brown SA, Coordinators AC (2018) Introduction. *Dev Cogn Neurosci* 32: The Adolescent Brain Cognitive Development (ABCD) Consortium: Rationale, aims, and assessment strategy:1–3
37. Farmer RFK, Seeley DB, Gau JR, Duncan JM, Walker SC, Lewinsohn DDPM (2016) Association of comorbid psycho-pathology with the duration of cannabis use disorders. *Psychol Addict Behav* 30(1):82–92 [PubMed: 26766543]
38. Agrawal A, Budney AJ, Lynskey MT (2012) The co-occurring use and misuse of cannabis and tobacco: a review. *Addiction*. 10.1111/j.1360-0443.2012.03837.x
39. Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C (2015) Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use. *Drug Alcohol Depend* 155:134–140. 10.1016/j.drugalcdep.2015.08.001 [PubMed: 26307942]
40. Florez-Salamanca L, Secades-Villa R, Hasin DS, Cottler L, Wang S, Grant BF, Blanco C (2013) Probability and predictors of transition from abuse to dependence on alcohol, cannabis, and cocaine: results from the national epidemiologic survey on alcohol and related conditions. *Am J Drug Alcohol Abuse* 39(3):168–179 [PubMed: 23721532]
41. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J (2013) Cannabis use and cannabis use disorders among individuals with mental illness. *Compr Psychiatry* 54(6):589–598 [PubMed: 23375264]
42. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C (2011) Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). *Drug Alcohol Depend* 115(1–2):120–130. 10.1016/j.drugalcdep.2010.11.004 [PubMed: 21145178]
43. Martins SS, Gorelick DA (2011) Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. *Drug Alcohol Depend* 119(1–2): 28–36 [PubMed: 21641123]
44. Cheung JT, Mann RE, Ialomiteanu A, Stoduto G, Chan V, Ala-Leppilampi K, Rehm J (2010) Anxiety and mood disorders and cannabis use. *Am J Drug Alcohol Abuse* 36(2):118–122. 10.3109/00952991003713784 [PubMed: 20337509]
45. Zvolensky MJ, Coughle JR, Johnson KA, Bonn-Miller MO, Bernstein A (2010) Marijuana use and panic psychopathology among a representative sample of adults. *Exp Clin Psychopharmacol* 18(2):129–134. 10.1037/a0019022 [PubMed: 20384424]
46. Degenhardt L, Hall W, Lynskey M (2001) The relationship between cannabis use, depression and anxiety among Australian adults: findings from the national survey of mental health and well-being. *Soc Psychiatry Psychiatr Epidemiol* 36(5):219–227. doi:10.1007/s001270170052 [PubMed: 11515699]

47. Stinson FS, Ruan WJ, Pickering R, Grant BF (2006) Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. *Psychol Med* 36(10):1447–1460. 10.1017/S0033291706008361 [PubMed: 16854249]
48. Borodovsky JT, Budney AJ (2018) Cannabis regulatory science: risk–benefit considerations for mental disorders. *Int Rev Psychiatry*:1–20. 10.1080/09540261.2018.1454406
49. Goldenberg M, Reid MW, IsHak WW, Danovitch I (2017) The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: a systematic review and meta-analysis. *Drug Alcohol Depend* 174:80–90 [PubMed: 28319753]
50. Montanari L, Guarita B, Mounteney J, Zipfel N, Simon R (2017) Cannabis use among people entering drug treatment in Europe: a growing phenomenon? *Eur Addict Res* 23(3):113–121 [PubMed: 28511182]
51. SAMHSA (2017) Treatment Episode Data Set (TEDS): 2005–2015 National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HHS Publication No. (SMA) 17–5037. Substance Abuse and Mental Health Services Administration, Rockville
52. SAMSHA (2004) Treatment Episode Data Set 2002 SPSS Data
53. SAMHSA (2017) Treatment Episode Data Set 2015 SPSS Data
54. Johnston LD, Miech RA, O'Malley PM, Bachman JG, Schulenberg JE, Patrick ME (2017) Monitoring the Future national survey results on drug use: 1975–2017: Overview, key findings on adolescent drug use. Institute for Social Research, The University of Michigan, Ann Arbor
55. Wu LT, Zhu H, Mannelli P, Swartz MS (2017) Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. *Drug Alcohol Depend* 177:153–162 [PubMed: 28599214]
56. Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS (2016) Epidemiology of DSM-5 drug use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. *JAMA Psychiatry* 73(1):39–47. 10.1001/jamapsychiatry.2015.2132 [PubMed: 26580136]
57. Blanco C, Iza M, Rodríguez-Fernández JM, Baca-García E, Wang S, Olfson M (2015) Probability and predictors of treatment-seeking for substance use disorders in the U.S. *Drug Alcohol Depend* 149:136–144 [PubMed: 25725934]
58. Gates P, Copeland J, Swift W, Martin G (2012) Barriers and facilitators to cannabis treatment. *Drug Alcohol Rev* 31(3):311–319. 10.1111/j.1465-3362.2011.00313.x [PubMed: 21521384]
59. van der Pol P, Liebrechts N, de Graaf R, Korf DJ, van den Brink W, van Laar M (2013) Facilitators and barriers in treatment seeking for cannabis dependence. *Drug Alcohol Depend* 133(2):776–780. 10.1016/j.drugalcdep.2013.08.011 [PubMed: 24035185]
60. Budney AJ, Radonovich KJ, Higgins ST, Wong CJ (1998) Adults seeking treatment for marijuana dependence: a comparison to cocaine-dependent treatment seekers. *Exp Clin Psychopharmacol* 6(4):419–426 [PubMed: 9861556]
61. Stephens RS, Babor TF, Kadden R, Miller M (2002) The marijuana treatment project: Rationale, design, and participant characteristics. *Addiction* 97(S1):109–124 [PubMed: 12460133]
62. Knapp AA, Babbitt SF, Budney AJ, Walker DD, Stephens RS, Scherer EA, Stanger C (2018) Psychometric assessment of the marijuana adolescent problem inventory. *Addict Behav* 79(4):113–119 [PubMed: 29288984]
63. WHO ASSIST Working Group (2002) The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. *Addiction* 97(9):1183–1194 [PubMed: 12199834]
64. Legleye S, Karila L, Beck F, Reynaud M (2007) Validation of the CAST, a general population cannabis abuse screening test. *J Subst Use* 12(4):233–242
65. Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, Sellman JD (2010) An improved brief measure of cannabis misuse: the cannabis use disorders identification test-revised (CUDIT-R). *Drug Alcohol Depend* 110(1–2):137–143. 10.1016/j.drugalcdep.2010.02.017 [PubMed: 20347232]
66. Martin G, Copeland J, Gilmour S, Gates P, Swift W (2006) The adolescent cannabis problems questionnaire (CPQ-A): psychometric properties. *Addict Behav* 31(12):2238–2248. 10.1016/j.addbeh.2006.03.001 [PubMed: 16626880]

67. Bashford J, Flett RJC (2010) The cannabis use problems identification test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults. *Addiction* 105(4):615–625 [PubMed: 20403014]
68. White HR, Labouvie EW, Papadaratsakis V (2005) Changes in substance use during the transition to adulthood: a comparison of college students and their noncollege age peers. *J Drug Issues* 35(2): 281–306
69. Fernandez-Artamendi S, Fernández-Hermida J, Muñoz-Fernández J, Secades-Villa R, García-Fernández G (2012) Screening of cannabis-related problems among youth: the CPQ-A-S and CAST questionnaires. *J Subst Abuse Treat Prev Policy* 7(1):13 10.1186/1747-597x-7-13
70. Halladay J, Petker T, Fein A, Munn C, MacKillop JJSR (2018) Brief interventions for cannabis use in emerging adults: protocol for a systematic review, meta-analysis, and evidence map. *Syst Rev* 7(1):106 10.1186/s13643-018-0772-z [PubMed: 30045752]
71. Hughes JR, Naud S, Budney AJ, Fingar JR, Callas PW (2016) Attempts to stop or reduce daily cannabis use: an intensive natural history study. *Psychol Addict Behav* 30(3):389–397. 10.1037/adb0000155 [PubMed: 26828641]
72. Hughes JR, Peters EN, Callas PW, Budney AJ, Livingston A (2008) Attempts to stop or reduce marijuana use in non-treatment seekers. *Drug Alcohol Depend* 97:180–184 [PubMed: 18485619]
73. Hughes JR, Fingar JR, Budney AJ, Naud S, Helzer JE, Callas PW (2014) Marijuana use and intoxication among daily users: an intensive longitudinal study. *Addict Behav* 39(10):1464–1470. 10.1016/j.addbeh.2014.05.024 [PubMed: 24935797]
74. Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, Callaghan B, Rana U, McLaren J (2010) Systematic review of prospective studies investigating “remission” from amphetamine, cannabis, cocaine or opioid dependence. *Addict Behav* 35(8):741–749 [PubMed: 20444552]
75. von Sydow K, Lieb R, Pfister H, Hofler M, Sonntag H, Wittchen H (2001) The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. *Drug Alcohol Depend* 64:347–361 [PubMed: 11672949]
76. Budney AJ, Vandrey R, Fearer SA (2011) Cannabis (marijuana) In: Ruiz P, Strain E (eds) Lowenson & Ruiz’s substance abuse: a comprehensive textbook, 5th edn Lippincott Williams & Wilkins, Baltimore, pp 214–237
77. Budney AJ, Vandrey RG, Stanger C (2010) Pharmacological and psychosocial interventions for cannabis use disorders. *Rev Bras Psiquiatr* 32(Suppl 1):S46–S55 [PubMed: 20512270]
78. Cooper K, Chatters R, Kaltenthaler E, Wong R (2015) Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. *Health Technol Assess* 19(56):1–130. 10.3310/hta19560
79. Danovitch I, Gorelick DA (2012) State of the art treatments for cannabis dependence. *Psychiatric Clin of N Am* 35(2):309–326. 10.1016/j.psc.2012.03.003
80. Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA (2015) Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. *Eval Health Prof* 38(1):94–114. 10.1177/0163278714529970 [PubMed: 24695072]
81. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L (2016) Psychosocial interventions for cannabis use disorder. *Cochrane Database Syst Rev* (5):CD005336 10.1002/14651858.CD005336.pub4
82. Sherman BJ, McRae-Clark AL (2016) Treatment of cannabis use disorder: current science and future outlook. *Pharmacotherapy* 36(5):511–535. 10.1002/phar.1747 [PubMed: 27027272]
83. Budney AJ, Stanger C, Knapp AA, Walker DD (2018) Status update on the treatment of cannabis use disorder In: Winters KC, Sabet KA (eds) *Contemporary health issues on marijuana*. Oxford University Press, New York, pp 236–255
84. Parmar A, Sarkar S (2017) Brief interventions for cannabis use disorders. *Rev Addict Dis Treat* 16(2):80–93
85. Budney AJ, Borodovsky JT, Marsch LA, Knapp AA (In press) Technological innovations in addiction treatment In: Danovitch I, Mooney L (eds) *The Assessment and Treatment of Addiction: Best Practices and New Frontiers*. Elsevier

86. Marsch LA, Carroll KM, Kiluk BD (2014) Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue. *J Subst Abuse Treat* 46(1): 1–4. 10.1016/j.jsat.2013.08.010 [PubMed: 24041749]
87. Schaub MP, Wenger A, Berg O, Beck T, Stark L, Buehler E, Haug S (2015) A web-based self-help intervention with and without chat counseling to reduce cannabis use in problematic cannabis users: three-arm randomized controlled trial. *J Med Internet Res* 17(10):e232 10.2196/jmir.4860 [PubMed: 26462848]
88. Hogue A, Henderson CE, Ozechowski TJ, Robbins MS (2014) Evidence base on outpatient behavioral treatments for adolescent substance use: updates and recommendations 2007–2013. *J Clin Child Adolesc Psychol* 43(5):695–720. 10.1080/15374416.2014.915550 [PubMed: 24926870]
89. Simpson AK, Magid V (2016) Cannabis use disorder in adolescence. *Child Adolesc Psychiatr Clin N Am* 25(3):431–443. 10.1016/j.chc.2016.03.003 [PubMed: 27338965]
90. Stanger C, Lansing AH, Budney AJ (2016) Advances in research on contingency management for adolescent substance use. *Child Adolesc Psychiatr Clin N Am* 25(4):645–659. 10.1016/j.chc.2016.05.002 [PubMed: 27613343]
91. Tanner-Smith EE, Wilson SJ, Lipsey MW (2013) The comparative effectiveness of outpatient treatment for adolescent substance abuse: a meta-analysis. *J Subst Abuse Treat* 44:145–158 [PubMed: 22763198]
92. Waldron HB, Turner CW (2008) Evidence-based psychosocial treatments for adolescent substance abuse. *J Clin Child Adolesc Psychol* 37(1):238–261. 10.1080/15374410701820133 [PubMed: 18444060]
93. Winters KC, Tanner-Smith EE, Bresani E, Meyers K (2014) Current advances in the treatment of adolescent drug use. *Adolesc Health Med Ther* 5:199–210. 10.2147/AHMT.S48053 [PubMed: 25429247]
94. Winters KC, Botzet AM, Fahnhorst T (2011) Advances in adolescent substance abuse treatment. *Curr Psychiatry Rep* 13(5):416–421. 10.1007/s11920-011-0214-2 [PubMed: 21701838]
95. Hogue A, Henderson CE, Becker SJ, Knight DK (2018) Evidence base on outpatient behavioral treatments for adolescent substance use, 2014–2017: outcomes, treatment delivery, and promising horizons. *J Clin Child Adolesc Psychol* 47(4):499–526. 10.1080/15374416.2018.1466307 [PubMed: 29893607]
96. Liddle HA, Rowe CL, Dakof GA, Ungaro RA, Henderson CE (2004) Early intervention for adolescent substance abuse: pre-treatment to posttreatment outcomes of a randomized clinical trial comparing multidimensional family therapy and peer group treatment. *J Psychoactive Drugs* 36(1): 49–63 [PubMed: 15152709]
97. Marsch LA, Borodovsky JT (2016) Technology-based interventions for preventing and treating substance use among youth. *Child Adolesc Psychiatric Clin N Am* 25(4):755–768. 10.1016/j.chc.2016.06.005
98. Gorelick DA (2016) Pharmacological treatment of cannabis-related disorders: a narrative review. *Curr Pharm Des* 22(42):6409–6419. 10.2174/1381612822666160822150822 [PubMed: 27549375]
99. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR (2017) A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. *Drug Alcohol Depend* 177:249–257. 10.1016/j.drugalcdep.2017.04.020 [PubMed: 28623823]
100. Copeland J, Pokorski I (2016) Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. *Subst Abuse Rehabil* 7:41–53. 10.2147/SAR.S89857 [PubMed: 27217809]
101. Mason BJ, Mustafa A, Filbey F, Brown ES (2016) Novel pharmacotherapeutic interventions for cannabis use disorder. *Curr Addict Rep* 3(2):214–220
102. Denis C, Lavie E, Fatseas M, Auriacombe M (2006) Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. *Cochrane Database Syst Rev* 3 10.1002/14651858.CD005336.pub2

103. Hall W, Lynskey M (2016) Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. *Lancet Psychiatry* 3(9):900–906 [PubMed: 27374072]
104. Wen H, Hockenberry JM, Druss BG (2018) The effect of medical marijuana laws on marijuana-related attitude and perception among US adolescents and young adults. *Prev Sci.* 10.1007/s1121-018-0903-8
105. Hasin DS (2017) US epidemiology of cannabis use and associated problems. *Neuropsychopharmacology* 43:195 10.1038/npp.2017.198 [PubMed: 28853439]
106. Carlini BH, Garrett SB, Harwick RM (2017) Beyond joints and brownies: Marijuana concentrates in the legal landscape of WA State. *Int J Drug Policy* 42:26–29. 10.1016/j.drugpo.2017.01.004 [PubMed: 28171805]
107. Borodovsky JT, Crosier BS, Lee DC, Sargent JD, Budney AJ (2016) Smoking, vaping, eating: is legalization impacting the way people use cannabis? *Int J Drug Policy* 36:141–147. 10.1016/j.drugpo.2016.02.022 [PubMed: 26992484]
108. Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ (2017) Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. *J Anal Toxicol* 41 1–17. 10.1093/jat/bkx012 [PubMed: 28130542]
109. Loflin M, Earleywine M (2014) A new method of cannabis ingestion: the dangers of dabs? *Addict Behav* 39(10):1430–1433. 10.1016/j.addbeh.2014.05.013 [PubMed: 24930049]
110. Volkow N, Baler R, Compton W, Weiss S (2014) Adverse health effects of marijuana use. *N Engl J Med* 370(23):2219–2227 [PubMed: 24897085]
111. Paul CL, Mee KJ, Judd TM, Walsh RA, Tang A, Penman A, Girgis A (2010) Anywhere, anytime: retail access to tobacco in New South Wales and its potential impact on consumption and quitting. *Soc Sci Med* 71(4):799–806. 10.1016/j.socscimed.2010.05.011 [PubMed: 20554363]
112. Casswell S, Morojele N, Williams PP, Chaiyasong S, Gordon R, Gray-Philip G, Viet Cuong P, MacKintosh AM, Halliday S, Railton R, Randerson S, Parry CDH (2018) The alcohol environment protocol: a new tool for alcohol policy. *Drug Alcohol Rev.* 10.1111/dar.12654
113. Bickel WK, Johnson MW, Koffarnus MN, MacKillop J, Murphy JG (2014) The behavioral economics of substance use disorders: reinforcement pathologies and their repair. *Annu Rev Clin Psychol* 10:641–677. 10.1146/annurev-clinpsy-032813-153724 [PubMed: 24679180]
114. Borodovsky JT, Lee DC, Crosier BS, Gabrielli JL, Sargent JD, Budney AJ (2017) U.S. cannabis legalization and use of vaping and edible products among youth. *Drug Alcohol Depend* 177:299–306. 10.1016/j.drugalcdep.2017.02.017 [PubMed: 28662974]
115. Lee DC, Crosier BS, Borodovsky JT, Sargent JD, Budney AJ (2016) Online survey characterizing vaporizer use among cannabis users. *Drug Alcohol Depend* 159:227–233. 10.1016/j.drugalcdep.2015.12.020 [PubMed: 26774946]
116. Borodovsky JT, Budney AJ (2017) Legal cannabis laws, home cultivation, and use of edible cannabis products: a growing relationship? *Int J Drug Policy* 50:102–110. 10.1016/j.drugpo.2017.09.014 [PubMed: 29102847]
117. Caulkins JP, Kilmer B, MacCoun RJ, Pacula RL, Reuter PH (2012) Design considerations for legalizing cannabis: lessons inspired by analysis of California’s proposition 19. *Addiction* 107(5):865–871 [PubMed: 21985069]
118. Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP (2014) Developing public health regulations for marijuana: lessons from alcohol and tobacco. *Am J Public Health* 104(6):1021–1028. 10.2105/AJPH.2013.301766 [PubMed: 24825201]
119. Chaloupka FJ, Straif K, Leon ME (2010) Effectiveness of tax and price policies in tobacco control. *Tobacco Control.* 10.1136/tc.2010.039982
120. Chaloupka FJ, Cummings KM, Morley CP, Horan JK (2002) Tax, price and cigarette smoking: Evidence from the tobacco documents and implications for tobacco company marketing strategies. *Tob Control* 11(suppl 1):I62–I72. 10.1136/tc.11.suppl_1.i62 [PubMed: 11893816]
121. Farrell S, Manning WG, Finch MD (2003) Alcohol dependence and the price of alcoholic beverages. *J Health Econ* 22(1):117–147 [PubMed: 12564720]

122. DiFranza JR, Wellman RJ, Sargent JD, Weitzman M, Hipple BJ, Winickoff JP, Tobacco Consortium CfCHRotAAoP (2006) Tobacco promotion and the initiation of tobacco use: assessing the evidence for causality. *Pediatrics* 117(6):e1237–e1248. 10.1542/peds.2005-1817 [PubMed: 16740823]
123. Pechmann C, Knight SJ (2002) An experimental investigation of the joint effects of advertising and peers on adolescents' beliefs and intentions about cigarette consumption. *J Consum Res* 29(1):5–19. 10.1086/339918
124. Landman A, Cortese DK, Glantz S (2008) Tobacco industry sociological programs to influence public beliefs about smoking. *Soc Sci Med* 66(4):970–981. 10.1016/j.socscimed.2007.11.007 [PubMed: 18164524]
125. Evans N, Farkas A, Gilpin E, Berry C, Pierce JP (1995) Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. *J Natl Cancer Inst* 87(20):1538–1545 [PubMed: 7563188]
126. Biener L, Siegel M (2000) Tobacco marketing and adolescent smoking: more support for a causal inference. *Am J Public Health* 90(3):407–411 [PubMed: 10705860]
127. DeWit DJ, Adlaf EM, Offord DR, Ogborne AC (2000) Age at first alcohol use: a risk factor for the development of alcohol disorders. *Am J Psychiatry* 157(5):745–750. 10.1176/appi.ajp.157.5.745 [PubMed: 10784467]
128. Chen C-Y, O'Brien MS, Anthony JC (2005) Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. *Drug Alcohol Depend* 79:11–22 [PubMed: 15943940]
129. Perkonig A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen H-U (2008) The natural course of cannabis use, abuse and dependence during the first decades of life. *Addiction* 103(3):439–449. 10.1111/j.1360-0443.2007.02064.x [PubMed: 18269364]
130. Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC (2008) Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. *Addiction* 103(8):1361–1370. 10.1111/j.1360-0443.2008.02246.x [PubMed: 18855826]
131. Agrawal A, Grant JD, Waldron M, Duncan AE, Scherrer JF, Lynskey MT, Madden PA, Bucholz KK, Heath AC (2006) Risk for initiation of substance use as a function of age of onset of cigarette, alcohol and cannabis use: findings in a midwestern female twin cohort. *Prev Med* 43(2):125–128. 10.1016/j.ypmed.2006.03.022 [PubMed: 16697036]
132. D'Amico EJ, Miles JNV, Tucker JS (2015) Gateway to curiosity: medical marijuana ads and intention and use during middle school. *Psychol Addict Behav* 29(3):613–619. 10.1037/adb0000094 [PubMed: 26030167]
133. Roditis ML, Delucchi K, Chang A, Halpern-Felsher B (2016) Perceptions of social norms and exposure to pro-marijuana messages are associated with adolescent marijuana use. *Prev Med* 93:171–176. 10.1016/j.ypmed.2016.10.013 [PubMed: 27746339]
134. Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min SJ, Sakai JT (2014) Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11. *Drug Alcohol Depend* 140:145–155. 10.1016/j.drugalcdep.2014.04.016 [PubMed: 24837585]
135. D'Amico EJ, Rodriguez A, Tucker JS, Pedersen ER, Shih RA (2018) Planting the seed for marijuana use: changes in exposure to medical marijuana advertising and subsequent adolescent marijuana use, cognitions, and consequences over seven years. *Drug Alcohol Depend* 188:385–391. 10.1016/j.drugalcdep.2018.03.031 [PubMed: 29779761]
136. Barry RA, Glantz S (2016) A public health framework for legalized retail marijuana based on the US experience: avoiding a new tobacco industry. *PLoS Med* 13(9):e1002131 10.1371/journal.pmed.1002131 [PubMed: 27676176]
137. Caulkins JP, Kilmer B, Kleiman MAR (2016) Marijuana legalization: What everyone needs to know, 2 edn Oxford University Press, New York 10.7249/CB525-1
138. Kilmer B (2014) Policy designs for cannabis legalization: starting with the eight Ps. *Am J Drug Alcohol Abuse* 40(4):259–261. 10.3109/00952990.2014.894047 [PubMed: 24853283]
139. Richter KP, Levy S (2014) Big marijuana—lessons from big tobacco. *N Engl J Med* 371(5):399–401. 10.1056/NEJMp1406074 [PubMed: 24918955]

Table 1**Summary points on cannabis use disorder (CUD) and its consequences***Does cannabis addiction exist and how do you define it?*

Cannabis (THC-laden products) has addictive potential

Cannabis use disorder (CUD) is diagnosed using either the ICD-10 or DSM-5 using the same criteria as for other substances

The manifestation of CUD is highly similar to that for other substance use disorders (SUDs)

How prevalent is CUD and how severe are its associated consequences?

The prevalence of CUD is comparable to other SUDs

CUD is more prevalent in high-income nations such as the U.S., Germany, and Australia

A substantial proportion, 11–30%, of those who use cannabis in the U.S. report having a CUD

CUD is associated with a myriad of psychosocial consequences and those who have CUD have increased odds of having other SUDs and psychiatric disorders

CUD, on average, may be less severe than other common SUDs

Do people seek treatment for CUD?

(1) Rates of treatment seeking globally and in the U.S. are comparable to the other SUDs

(2) Treatment admission rates appear to be lower in the U.S. compared to most European nations and Australia

(3) Those with CUD appear to seek treatment at lower rates than for other SUDs

How difficult is quitting or reducing cannabis use?

Short-term studies of those who use cannabis daily and are interested in quitting suggest that quit and reduction attempts are frequent and short lived, and achievement of sustained abstinence is rare
Behavioral interventions for CUD are efficacious (e.g., MET, CBT, CM, and integrated combinations), however, only the minority respond to treatment and relapse rates are high

The development and implementation of more effective strategies for prevention and treatment of CUD is much needed, particularly given this dynamically changing legislative climate

What impact will the changing legal environment have on the development of CUD?

Changing laws and regulations are highly likely to impact the development of CUD and its course, and perhaps treatment seeking

Definitive data on the effects of changes in the cannabis legal environment are not yet available; the constant fluctuations in the legislative and regulatory environment make this area of study difficult and the interpretation of current findings challenging

Each question and the corresponding answers above represent the five main sections of the current overview